OcuSoft, I-Med partner to bring I-Pen osmolarity system to US

OcuSoft has entered a distribution agreement with I-Med Pharma to distribute the I-Pen tear osmolarity system in the United States, according to a press release.

The I-Pen, a hand-held device that measures the osmolarity of human tears in normal and dry eye disease patients, received an acceptance review notification from the FDA on Dec. 22, 2017.

The partnership will officially begin when the I-Pen’s 510(k) submission receives final FDA clearance, which is expected in the first quarter of this year.

OcuSoft has entered a distribution agreement with I-Med Pharma to distribute the I-Pen tear osmolarity system in the United States, according to a press release.

The I-Pen, a hand-held device that measures the osmolarity of human tears in normal and dry eye disease patients, received an acceptance review notification from the FDA on Dec. 22, 2017.

The partnership will officially begin when the I-Pen’s 510(k) submission receives final FDA clearance, which is expected in the first quarter of this year.